Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hyperglycemia | 18 | 2021 | 1363 | 4.76 | Why? |
| Hypoglycemic Agents | 23 | 2021 | 2165 | 4.67 | Why? |
| Insulin | 18 | 2021 | 1316 | 3.44 | Why? |
| Blood Glucose | 34 | 2021 | 3642 | 3.30 | Why? |
| Diabetes Mellitus, Type 2 | 24 | 2021 | 6166 | 3.21 | Why? |
| Insulin Glargine | 5 | 2018 | 43 | 2.91 | Why? |
| Diabetic Ketoacidosis | 9 | 2021 | 622 | 2.76 | Why? |
| Hypoglycemia | 12 | 2020 | 406 | 2.50 | Why? |
| Sitagliptin Phosphate | 3 | 2018 | 82 | 2.04 | Why? |
| Diabetes Mellitus, Type 1 | 8 | 2021 | 1969 | 1.90 | Why? |
| Diabetes Mellitus | 15 | 2021 | 8207 | 1.69 | Why? |
| Insulin Infusion Systems | 8 | 2021 | 256 | 1.50 | Why? |
| Glycated Hemoglobin A | 10 | 2021 | 1316 | 1.42 | Why? |
| Hyperglycemic Hyperosmolar Nonketotic Coma | 2 | 2017 | 58 | 1.25 | Why? |
| Endocrinologists | 3 | 2019 | 67 | 1.06 | Why? |
| Stress, Physiological | 2 | 2018 | 378 | 1.04 | Why? |
| Insulins | 2 | 2019 | 26 | 0.95 | Why? |
| Blood Glucose Self-Monitoring | 9 | 2021 | 791 | 0.93 | Why? |
| Endocrinology | 4 | 2018 | 252 | 0.92 | Why? |
| Insulin, Short-Acting | 2 | 2018 | 16 | 0.92 | Why? |
| Linagliptin | 2 | 2018 | 22 | 0.92 | Why? |
| Prediabetic State | 3 | 2018 | 200 | 0.86 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 4 | 2018 | 436 | 0.85 | Why? |
| Metformin | 2 | 2018 | 640 | 0.82 | Why? |
| Glucagon-Like Peptides | 1 | 2019 | 29 | 0.78 | Why? |
| Insulin Detemir | 1 | 2017 | 10 | 0.72 | Why? |
| Diet Therapy | 1 | 2018 | 66 | 0.68 | Why? |
| Sodium-Glucose Transporter 2 | 1 | 2017 | 111 | 0.66 | Why? |
| Consensus | 5 | 2020 | 6345 | 0.64 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2017 | 138 | 0.61 | Why? |
| Intraoperative Complications | 1 | 2018 | 221 | 0.59 | Why? |
| Diabetic Angiopathies | 1 | 2017 | 146 | 0.57 | Why? |
| Immunoglobulin Fc Fragments | 1 | 2019 | 691 | 0.56 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2017 | 205 | 0.55 | Why? |
| Inpatients | 7 | 2020 | 5161 | 0.53 | Why? |
| Recombinant Fusion Proteins | 1 | 2019 | 919 | 0.53 | Why? |
| Endocrine System Diseases | 1 | 2017 | 282 | 0.52 | Why? |
| Algorithms | 4 | 2021 | 7346 | 0.48 | Why? |
| Postoperative Complications | 4 | 2018 | 5861 | 0.47 | Why? |
| Ambulatory Surgical Procedures | 1 | 2016 | 444 | 0.46 | Why? |
| African Americans | 3 | 2018 | 3363 | 0.46 | Why? |
| Preoperative Care | 2 | 2018 | 1515 | 0.44 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.43 | Why? |
| Fat Emulsions, Intravenous | 1 | 2009 | 14 | 0.41 | Why? |
| Coronary Artery Bypass | 1 | 2017 | 629 | 0.41 | Why? |
| Perioperative Care | 2 | 2018 | 1329 | 0.40 | Why? |
| Atherosclerosis | 1 | 2017 | 768 | 0.39 | Why? |
| Disease Management | 4 | 2021 | 6841 | 0.38 | Why? |
| Diabetes Complications | 6 | 2021 | 2358 | 0.38 | Why? |
| Insulin-Secreting Cells | 2 | 2018 | 273 | 0.37 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.37 | Why? |
| Learning | 1 | 2017 | 1181 | 0.36 | Why? |
| Food Supply | 1 | 2017 | 1027 | 0.36 | Why? |
| Monitoring, Physiologic | 4 | 2021 | 1956 | 0.35 | Why? |
| Surgical Procedures, Operative | 2 | 2018 | 2662 | 0.30 | Why? |
| Emergencies | 2 | 2017 | 4095 | 0.28 | Why? |
| Peptides | 1 | 2017 | 2513 | 0.28 | Why? |
| Social Determinants of Health | 1 | 2017 | 1757 | 0.28 | Why? |
| Stress, Psychological | 2 | 2018 | 10231 | 0.28 | Why? |
| Humans | 55 | 2021 | 930598 | 0.28 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.27 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.27 | Why? |
| Hospitals | 5 | 2020 | 11793 | 0.25 | Why? |
| Hospitalization | 9 | 2021 | 54280 | 0.25 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.24 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.23 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.23 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.23 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.23 | Why? |
| Fluid Therapy | 2 | 2017 | 628 | 0.23 | Why? |
| Acute Kidney Injury | 2 | 2021 | 5762 | 0.22 | Why? |
| Societies, Medical | 4 | 2018 | 6907 | 0.21 | Why? |
| Postprandial Period | 1 | 2019 | 45 | 0.20 | Why? |
| Pilot Projects | 3 | 2021 | 5182 | 0.19 | Why? |
| Patient Education as Topic | 3 | 2018 | 1476 | 0.19 | Why? |
| Equipment and Supplies | 2 | 2021 | 440 | 0.19 | Why? |
| Systems Integration | 1 | 2018 | 72 | 0.18 | Why? |
| Exercise | 2 | 2018 | 6771 | 0.18 | Why? |
| 3-Hydroxybutyric Acid | 1 | 2017 | 16 | 0.18 | Why? |
| Patient Discharge | 3 | 2019 | 5696 | 0.18 | Why? |
| Bicarbonates | 1 | 2017 | 33 | 0.17 | Why? |
| Proprotein Convertase 9 | 1 | 2019 | 141 | 0.17 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.17 | Why? |
| Remote Sensing Technology | 1 | 2021 | 351 | 0.16 | Why? |
| Drug Administration Schedule | 2 | 2016 | 2324 | 0.16 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.16 | Why? |
| Dehydration | 1 | 2016 | 51 | 0.15 | Why? |
| Diabetic Cardiomyopathies | 1 | 2017 | 79 | 0.15 | Why? |
| Critical Illness | 5 | 2021 | 17281 | 0.15 | Why? |
| Colombia | 1 | 2021 | 1241 | 0.15 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.15 | Why? |
| Hypolipidemic Agents | 1 | 2018 | 208 | 0.15 | Why? |
| Data Accuracy | 1 | 2021 | 715 | 0.15 | Why? |
| Triazines | 1 | 2018 | 246 | 0.15 | Why? |
| Glucose Tolerance Test | 1 | 2016 | 238 | 0.15 | Why? |
| Aged | 15 | 2021 | 215776 | 0.15 | Why? |
| Education, Nursing, Continuing | 1 | 2017 | 129 | 0.15 | Why? |
| Intention to Treat Analysis | 1 | 2017 | 673 | 0.15 | Why? |
| Hyperlipidemias | 1 | 2018 | 290 | 0.15 | Why? |
| Telemetry | 1 | 2017 | 240 | 0.14 | Why? |
| Female | 22 | 2021 | 380317 | 0.14 | Why? |
| Male | 21 | 2021 | 367725 | 0.14 | Why? |
| Length of Stay | 3 | 2017 | 11042 | 0.14 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.14 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.14 | Why? |
| Life Style | 2 | 2018 | 2708 | 0.14 | Why? |
| Insulin Resistance | 2 | 2018 | 669 | 0.14 | Why? |
| Health Education | 2 | 2017 | 1539 | 0.13 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.13 | Why? |
| Hospital Costs | 1 | 2017 | 274 | 0.13 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.13 | Why? |
| Cardiovascular Diseases | 2 | 2021 | 11497 | 0.13 | Why? |
| Fasting | 1 | 2019 | 555 | 0.13 | Why? |
| Residential Facilities | 1 | 2017 | 443 | 0.12 | Why? |
| Pediatric Obesity | 1 | 2018 | 492 | 0.12 | Why? |
| Single-Blind Method | 1 | 2016 | 1283 | 0.12 | Why? |
| Computers, Handheld | 1 | 2014 | 242 | 0.12 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.12 | Why? |
| Obesity | 4 | 2021 | 7388 | 0.11 | Why? |
| Counseling | 1 | 2018 | 747 | 0.11 | Why? |
| Self Care | 2 | 2017 | 918 | 0.11 | Why? |
| Feasibility Studies | 2 | 2018 | 3467 | 0.11 | Why? |
| Pancreatic Function Tests | 1 | 2009 | 3 | 0.11 | Why? |
| Unemployment | 1 | 2017 | 702 | 0.10 | Why? |
| Education, Medical, Continuing | 1 | 2017 | 638 | 0.10 | Why? |
| United States | 6 | 2021 | 46150 | 0.10 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.10 | Why? |
| Patient Readmission | 1 | 2019 | 1543 | 0.10 | Why? |
| Precision Medicine | 1 | 2020 | 1477 | 0.10 | Why? |
| Smoking Cessation | 1 | 2018 | 826 | 0.10 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.10 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.10 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.09 | Why? |
| Treatment Outcome | 5 | 2018 | 51732 | 0.09 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.09 | Why? |
| Skilled Nursing Facilities | 1 | 2017 | 1098 | 0.09 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.09 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.09 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.09 | Why? |
| Diet | 2 | 2018 | 2052 | 0.09 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Income | 1 | 2017 | 1564 | 0.08 | Why? |
| Malnutrition | 1 | 2017 | 932 | 0.08 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.08 | Why? |
| Arginine | 1 | 2009 | 377 | 0.08 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.08 | Why? |
| Risk Reduction Behavior | 1 | 2014 | 946 | 0.08 | Why? |
| Health Literacy | 1 | 2017 | 1078 | 0.08 | Why? |
| Health Personnel | 1 | 2017 | 29646 | 0.08 | Why? |
| Remission Induction | 1 | 2009 | 950 | 0.08 | Why? |
| Adult | 11 | 2021 | 244371 | 0.08 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.08 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.07 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.07 | Why? |
| Sleep | 1 | 2018 | 2695 | 0.07 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.07 | Why? |
| Academic Medical Centers | 1 | 2017 | 3088 | 0.07 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.07 | Why? |
| Withholding Treatment | 1 | 2009 | 798 | 0.06 | Why? |
| Body Mass Index | 1 | 2016 | 4306 | 0.06 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.06 | Why? |
| Acid-Base Equilibrium | 1 | 2021 | 53 | 0.05 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.05 | Why? |
| Longitudinal Studies | 1 | 2016 | 9893 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.05 | Why? |
| Calibration | 1 | 2020 | 307 | 0.05 | Why? |
| Young Adult | 4 | 2018 | 93724 | 0.05 | Why? |
| Drug Dosage Calculations | 1 | 2020 | 243 | 0.05 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.05 | Why? |
| Proof of Concept Study | 1 | 2021 | 696 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.04 | Why? |
| Anthropometry | 1 | 2018 | 233 | 0.04 | Why? |
| Point-of-Care Systems | 2 | 2021 | 2955 | 0.04 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.04 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.04 | Why? |
| Monitoring, Ambulatory | 1 | 2020 | 343 | 0.04 | Why? |
| Amputation | 1 | 2018 | 331 | 0.04 | Why? |
| Hypertension | 1 | 2018 | 8895 | 0.04 | Why? |
| Georgia | 1 | 2018 | 955 | 0.03 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Gynecologic Surgical Procedures | 1 | 2018 | 489 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2020 | 1276 | 0.03 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.03 | Why? |
| Digestive System Surgical Procedures | 1 | 2018 | 677 | 0.03 | Why? |
| Behavior Therapy | 1 | 2014 | 235 | 0.03 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.03 | Why? |
| Social Perception | 1 | 2014 | 371 | 0.03 | Why? |
| Urologic Surgical Procedures | 1 | 2018 | 996 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.02 | Why? |
| Self Efficacy | 1 | 2014 | 717 | 0.02 | Why? |
| Orthopedic Procedures | 1 | 2018 | 1231 | 0.02 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.02 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Motivation | 1 | 2014 | 1640 | 0.02 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Biomarkers | 1 | 2019 | 23361 | 0.01 | Why? |
| Time Factors | 1 | 2019 | 31397 | 0.01 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Risk Assessment | 1 | 2014 | 25439 | 0.01 | Why? |
Umpierrez's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(81)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_